The FDA granted fast track designation to SC291 as a potential treatment for hard-to-manage systemic lupus erythematosus (SLE).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback